2026 Global: Biosimulation Market-Competitive Review (2032) report
Description
The 2026 Global: Biosimulation Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biosimulation market by geography and historical trend. The scope of the report extends to sizing of the biosimulation market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Certara, Simulations Plus, Dassault Systèmes, Schrödinger, Genedata, Advanced Chemistry Development (ACD/Labs), Chemical Computing Group (CCG), Physiomics, Rosa & Co., and VeriSIM Life are among the ten major companies shaping the global biosimulation market, each providing distinct platforms and services that accelerate drug discovery and development. Certara is a leader in Model-Informed Drug Development (MIDD) offering integrated pharmacometrics, regulatory science, and market-access solutions that span preclinical through clinical stages and serve thousands of customers worldwide. Simulations Plus supplies modeling and simulation software for ADMET, pharmacokinetics, and PK/PD that are widely used by pharma and biotech to predict absorption, distribution, metabolism, excretion, and toxicity outcomes during candidate selection and development. Dassault Systèmes, through its BIOVIA and SIMULIA brands within the 3DEXPERIENCE platform, delivers multiphysics and molecular modeling capabilities that support materials, biologics, and process simulation across R&D and manufacturing. Schrödinger focuses on high‑performance molecular simulation and computational chemistry software and operates a dual software and drug‑discovery business that enables structure‑based and ligand‑based design workflows for small molecules and biologics.
Genedata, ACD/Labs, and Chemical Computing Group provide enterprise bioinformatics and cheminformatics solutions that underpin large‑scale data management, assay analysis, and molecular modeling used in biosimulation pipelines. Genedata offers full‑stack enterprise infrastructure for biologics, screening, omics, and trial data to accelerate R&D workflows and integrate high‑throughput and clinical data streams. ACD/Labs supplies cheminformatics, spectral interpretation, and ADMET prediction tools that feed into in silico safety and metabolism modeling, while CCG’s molecular modeling suites support quantum mechanics, docking, and conformational analysis used in ligand design and virtual screening. Physiomics (now part of a broader services ecosystem) specializes in systems pharmacology and PK/PD modeling to predict efficacy and optimize dosing in translational and clinical settings, enabling sponsors to de‑risk development decisions and support regulatory interactions. Rosa & Co. provides mechanistic modeling and simulation services for cardiovascular, metabolic, and respiratory systems, combining physiological models with pharmacokinetic modeling to simulate disease progression and treatment response. VeriSIM Life applies AI‑driven mechanistic and virtual twin approaches to create predictive in silico models for translational and clinical outcomes, integrating real‑world and trial data to support go/no‑go decisions and trial design optimization.
Collectively these companies advance biosimulation through complementary software platforms, curated model libraries, mechanistic systems pharmacology, and regulatory‑grade workflows that reduce reliance on costly in vivo studies and shorten timelines to IND/CTA and beyond. Their strategies include platform enhancements, acquisitions, and partnerships to expand capabilities—Certara’s integration of generative AI with MIDD and Dassault’s cross‑industry simulation breadth are examples of differentiated approaches to deliver end‑to‑end modeling support for drug discovery, development, and commercialization. Industry adoption spans biopharma, CROs, and regulators, with biosimulation increasingly embedded into portfolio prioritization, trial design, and labeling strategies to improve predictability and cost efficiency in drug development.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biosimulation market by geography and historical trend. The scope of the report extends to sizing of the biosimulation market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Certara, Simulations Plus, Dassault Systèmes, Schrödinger, Genedata, Advanced Chemistry Development (ACD/Labs), Chemical Computing Group (CCG), Physiomics, Rosa & Co., and VeriSIM Life are among the ten major companies shaping the global biosimulation market, each providing distinct platforms and services that accelerate drug discovery and development. Certara is a leader in Model-Informed Drug Development (MIDD) offering integrated pharmacometrics, regulatory science, and market-access solutions that span preclinical through clinical stages and serve thousands of customers worldwide. Simulations Plus supplies modeling and simulation software for ADMET, pharmacokinetics, and PK/PD that are widely used by pharma and biotech to predict absorption, distribution, metabolism, excretion, and toxicity outcomes during candidate selection and development. Dassault Systèmes, through its BIOVIA and SIMULIA brands within the 3DEXPERIENCE platform, delivers multiphysics and molecular modeling capabilities that support materials, biologics, and process simulation across R&D and manufacturing. Schrödinger focuses on high‑performance molecular simulation and computational chemistry software and operates a dual software and drug‑discovery business that enables structure‑based and ligand‑based design workflows for small molecules and biologics.
Genedata, ACD/Labs, and Chemical Computing Group provide enterprise bioinformatics and cheminformatics solutions that underpin large‑scale data management, assay analysis, and molecular modeling used in biosimulation pipelines. Genedata offers full‑stack enterprise infrastructure for biologics, screening, omics, and trial data to accelerate R&D workflows and integrate high‑throughput and clinical data streams. ACD/Labs supplies cheminformatics, spectral interpretation, and ADMET prediction tools that feed into in silico safety and metabolism modeling, while CCG’s molecular modeling suites support quantum mechanics, docking, and conformational analysis used in ligand design and virtual screening. Physiomics (now part of a broader services ecosystem) specializes in systems pharmacology and PK/PD modeling to predict efficacy and optimize dosing in translational and clinical settings, enabling sponsors to de‑risk development decisions and support regulatory interactions. Rosa & Co. provides mechanistic modeling and simulation services for cardiovascular, metabolic, and respiratory systems, combining physiological models with pharmacokinetic modeling to simulate disease progression and treatment response. VeriSIM Life applies AI‑driven mechanistic and virtual twin approaches to create predictive in silico models for translational and clinical outcomes, integrating real‑world and trial data to support go/no‑go decisions and trial design optimization.
Collectively these companies advance biosimulation through complementary software platforms, curated model libraries, mechanistic systems pharmacology, and regulatory‑grade workflows that reduce reliance on costly in vivo studies and shorten timelines to IND/CTA and beyond. Their strategies include platform enhancements, acquisitions, and partnerships to expand capabilities—Certara’s integration of generative AI with MIDD and Dassault’s cross‑industry simulation breadth are examples of differentiated approaches to deliver end‑to‑end modeling support for drug discovery, development, and commercialization. Industry adoption spans biopharma, CROs, and regulators, with biosimulation increasingly embedded into portfolio prioritization, trial design, and labeling strategies to improve predictability and cost efficiency in drug development.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.